Why the study?
High-risk patients under 75 years with severe symptomatic aortic stenosis are eligible for both TAVR and iSAVR, but comparative outcome data are scarce.
Does TAVR improve short- and long-term survival compared to iSAVR in young, high-risk patients with severe symptomatic aortic stenosis?
Cohort (n=144)
No
Does TAVR improve short- and long-term survival compared to iSAVR in young, high-risk patients with severe symptomatic aortic stenosis?
This study indicates that while TAVR provides a short-term survival benefit for non-geriatric high-risk patients, SAVR results in superior long-term survival, suggesting that those likely to survive surgery may benefit more from the surgical approach.
Background: Younger patients with severe symptomatic aortic stenosis are a particularly challenging collective with regard to the choice of intervention. High-risk patients younger than 75 years of age are often eligible for both the transcatheter aortic valve replacement (TAVR) and the isolated surgical aortic valve replacement (iSAVR). Data on the outcomes of both interventions in this set of patients are scarce. Methods: One hundred and forty-four propensity score-matched patients aged 75 years or less who underwent TAVR or iSAVR at the Hietzing Heart Center in Vienna, Austria, were included in the study. The mean age was 68.9 years (TAVR 68.7 vs. SAVR 67.6 years; p = 0.190) and the average EuroSCORE II was 5.4% (TAVR 4.3 [3.2%] vs. iSAVR 6.4 (4.3%); p = 0.194). Results: Postprocedural adverse event data showed higher rates of newly acquired atrial fibrillation (6.9% vs. 19.4%; p = 0.049), prolonged ventilation (2.8% vs. 25.0%; p < 0.001) and multi-organ failure (0% vs. 6.9%) in the surgical cohort. The in-hospital and 30-day mortality was significantly higher for iSAVR (1.4% vs. 13.9%; p = 0.012; 12.5% vs. 2.8%; p = 0.009, respectively). The long-term survival (median follow-up 5.0 years (2.2–14.1 years)) of patients treated with the surgical approach was superior to that of patients undergoing TAVR (p < 0.001). Conclusion: Although the survival analysis revealed a higher in-hospital and 30-day survival rate for high-risk patients aged ≤75 years who underwent TAVR, iSAVR was associated with a significantly higher long-term survival rate.
No takes yet. Share an insight, caveat, or question.
Mach et al. (2021) conducted a cohort in Severe symptomatic aortic stenosis in high-risk patients (n=144). Transcatheter aortic valve replacement (TAVR) vs. Isolated surgical aortic valve replacement (iSAVR) was evaluated on 30-day all-cause mortality (p=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: